OSA pharmacotherapy reduces disease severity

A combination pharmacotherapy for obstructive sleep apnea led to greater reductions in disease severity compared with placebo, according to results from a proof-of-concept phase 2 trial.
According to a press release, IHL-42X (Incannex Healthcare) comprises two ingredients that have been proven to lower apnea hypopnea index (AHI): dronabinol, or synthetic tetrahydrocannabinol (THC), and acetazolamide.
“Incannex’s discovery that dronabinol and acetazolamide act synergistically to treat OSA, reducing AHI and improving patient-reported sleep quality, are the foundations of the IHL-42X

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.